ClinicalTrials.gg
CompletedNCT06269484ZEAL UNLOCKUpdated Jan 20, 2026Results posted

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

A Phase 2 interventional study of Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) and Zibotentan + placebo (placebo matching dapagliflozin tablet) in Liver Cirrhosis, sponsored by AstraZeneca. Completed at 34 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.

Enrollment
4th of 11
73 · median 40
Started
2024
with 2 others
Phase 2
6 of 11
1 open now
Registered
4th of 11
by date

Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 4th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 2, and was the 4th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin and zibotentan monotherapy as compared to placebo in patients with cirrhosis.

Read the detailed description

The study is designed to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin in combination and zibotentan monotherapy as compared to placebo in patients with cirrhosis with or without a history of decompensation. The study will be conducted in approximately 52 study centers in North America, Asia and Europe.

03

Conditions studied

  • Liver Cirrhosis

Keywords

  • Cirrhosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

≥ 18 and ≤ 80 years of age at the time of signing the .

Clinical and/or histological diagnosis of cirrhosis.

Note: Either history of decompensation or compensated cirrhosis with signs of CSPH, including varices at endoscopy or collaterals at imaging (within 12 months prior to screening), and/or liver stiffness using vibration controlled elastography, liver stiffness > 25 kPa or > 21 kPa, and \< 150 × 10\^99 (at time of screening).

Model for end stage liver disease score (MELD) \< 15.

score \< 10.

No ascites or ascites up to grade 2 without change in diuretic treatment within the last month prior to first dose of study intervention and no paracentesis within the last month.

No evidence of worsening of hepatic function (eg, no change in signs, symptoms, or laboratory parameters of hepatic disease status) within the last month prior to dosing, as determined by the investigator or usual practitioner.

No current or prior (within 1 month of enrolment) medical treatment with an SGLT2 inhibitor or endothelin receptor antagonist.

On no or a stable dose of beta blockers, with no major dose changes within 1 month prior to the first dose of study intervention.

Males or females of non-:

Male participants must be surgically sterile, abstinent, or must use in conjunction with their female partner a highly effective method of from the time they sign the informed consent document and for 3 months after the last dose of study intervention to prevent pregnancy in a partner. In addition, the male participant should use a condom for the duration of the study and for 3 months after the last dose of study intervention. Male participants must not donate or bank sperm during the same period.

Highly effective birth control methods are defined as those that can achieve a failure rate of less than 1% per year when used consistently and correctly.

Female participants must be of non-childbearing potential confirmed at screening by fulfilling one of the following criteria:

: defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments; and also FSH levels in the post-menopausal range by central laboratory (Note: The post-menopausal range must be checked against the specific FSH assay used). In the absence of 12 months of amenorrhoea, a single FSH measurement is insufficient to define post-menopausal criteria. In case of perimenopause or infrequent periods with variable levels of FSH, women should be considered of childbearing potential and, therefore, not eligible for participation in this study.

Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.

Female participants must have a negative pregnancy test at screening and must not be lactating.

Capable of giving signed informed consent as described in Appendix A, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Provision of signed and dated, written ICF prior to any mandatory study-specific procedures, sampling, and analyses.

Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics initiative research that supports Genomic Initiative.

Exclusion criteria

Exclusion criteria:

Any evidence of a disease, which in the investigator's opinion makes it undesirable for the participant to participate in the study.

/transaminase or AST ≥ 150 U/L and/or total

≥ 3 × .

> 1.7.

Serum/plasma levels of albumin ≤ 28 g/L.

count \< 50 × 109L.

Acute kidney injury (AKI) within 3 months of screening.

History of encephalopathy of West Haven Grade 2 or higher

History of variceal haemorrhage within 6 months prior to screening.

Any history of hepatocellular carcinoma.

Any history of portal venous thrombosis.

Liver transplant or expected liver transplantation within 6 months of screening.

History of TIPS or a planned TIPS within 6 months from enrolment into the study.

Positive alcohol breath test or screen for drugs of abuse (excluding drugs prescribed by the participants' usual physician) at screening.

Ongoing or history of significant use of alcohol expected to preclude correct adherence to study procedures (For details, refer to Section 5.3.2).

Active treatment for within the last 1 year or anti-viral therapy for less than 1 year.

Active urinary tract infection or genital infection.

Uncontrolled diabetes mellitus ( > 8.5% or > 69 mmol/mol within the last month).

Participants with T1DM.

Renal transplant or chronic renal replacement therapy or short-term dialysis within the previous 6 months.

\< 60 mL/min/1.73m2 (eGFRcr[AS]).

Acute coronary syndrome events within 3 months prior to screening.

Orthostatic hypotension or hypotension (systolic blood pressure \< 95 mmHg or diastolic blood pressure \< 60 mmHg).

functional heart failure Class III or IV or patients with unstable heart failure requiring hospitalisation for optimisation of heart failure treatment and who are not yet stable on heart failure therapy within 6 months prior to screening.

Heart failure due to cardiomyopathies that would primarily require specific other treatment.

High output heart failure (eg, due to hyperthyroidism or Paget's disease).

Heart failure due to primary cardiac valvular disease/dysfunction, severe functional mitral or tricuspid valve insufficiency, or planned cardiac valve repair/replacement.

Participants treated with strong inhibitor or strong or moderate CYP3A4 inducer within 14 days (St. John's Wort: 21 days) of study intervention administration; this includes grapefruit and grapefruit juice, if consumed more often than occasionally, or, in larger quantities.

History or ongoing allergy/, as judged by the investigator, to SGLT2 inhibitors (eg, dapagliflozin, canagliflozin, empagliflozin), zibotentan, or drugs with a similar chemical structure to zibotentan.

Any clinically significant chronic disease or disorder (eg, cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, psychiatric, major physical impairment) which, as judged by the investigator, might put the participant at risk because of participation in the study, or probable alternative primary reason for participant's symptoms in judgment of investigator.

Acute liver injury caused by drug toxicity or by an infection.

Implanted electronic device such as pacemaker.

Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study centre).

Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

Male participant in a sexually active relation with pregnant or breastfeeding partner.

Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

Exclusion Criteria for Participants Consenting to Optional Genetic Sampling:

Previous bone marrow transplant.

Non-leukocyte depleted whole blood transfusion in 120 days of genetic sample collection.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Placebo comparator
    Treatment Group 1

    Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks

    Drug: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)

  • Experimental
    Treatment Group 2

    Participants will receive once daily zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks

    Drug: Zibotentan + placebo (placebo matching dapagliflozin tablet)

  • Experimental
    Treatment Group 3

    Participants will receive once daily zibotentan capsule + dapagliflozin tablet 10 mg for 6 weeks

    Drug: Zibotentan + dapagliflozin

Interventions

  • DrugPlacebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)

    placebo capsule (matching zibotentan capsule) placebo tablet (matching dapagliflozin tablet)

  • DrugZibotentan + placebo (placebo matching dapagliflozin tablet)

    zibotentan capsule placebo tablet (matching dapagliflozin tablet)

  • DrugZibotentan + dapagliflozin

    Drug pages: ZD4054 · Dapagliflozin

    zibotentan capsule dapagliflozin 10 mg tablet

06

What researchers measure

Primary outcomes

  1. Cumulative Number of Subjects With Any of the Components of the Composite Endpoint: >2kg Increase in Body Weight (Office-based), >2 L Increase in Total Body Water, Increase in 2 or More Loop-diuretic Equivalents, Fluid Retention Adverse Event (AE)

    Cumulative number of subjects with event of composite fluid retention endpoint

    Time frame: baseline to Week 6

Secondary outcomes

  1. Change From Baseline in Body Weight

    Change in site body weight

    Time frame: at Week 6

  2. Change From Baseline in Body Fat Mass

    Time frame: at Week 6

  3. Change From Baseline in Total Body Water

    Time frame: at Week 6

  4. Change From Baseline in Extracellular Water Volume

    Time frame: at Week 6

  5. Change From Baseline in Intracellular Water Volume

    Time frame: at Week 6

  6. Change in Body Weight (kg) Over Time Course of Study

    Change in home body weight

    Time frame: at Week 6

  7. Change in Total Dosage of Loop-diuretic Equivalents Use

    One loop-diuretic equivalent = 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid. In Japan, one loop-diuretic equivalent = 40 mg furosemide = 8 mg torsemide = 60 mg azosemide.

    Time frame: at Week 6

  8. Cumulative Number of Subjects With Either of the Two Components of This Composite: 1. >3 L Increase in Total Body Water Volume From Baseline to Week 6 2. Increase in 3 or More Loop-diuretics Equivalents Use

    Cumulative number of subjects with event of composite and the components of total body water and total dosage of loop-diuretic equivalents

    Time frame: from baseline to Week 6

  9. Absolute Change in Systolic Blood Pressure

    Time frame: at Week 6

  10. Absolute Change in Diastolic Blood Pressure

    Time frame: at Week 6

07

Results

Posted Jan 20, 2026

Participant flow

The first participant was enrolled on February 2024 and the last participant was enrolled in September 2024.

Participant flow — Overall Study
MilestoneZibo/DapaZiboPlacebo
Started242524
Treated242424
Completed202422
Not completed412
Withdrew: Withdrawal by subject302
Withdrew: All other reasons apart from specified100
Withdrew: Randomised but not started treatment010

Outcome measures

PrimaryCumulative Number of Subjects With Any of the Components of the Composite Endpoint: >2kg Increase in Body Weight (Office-based), >2 L Increase in Total Body Water, Increase in 2 or More Loop-diuretic Equivalents, Fluid Retention Adverse Event (AE)

Cumulative number of subjects with event of composite fluid retention endpoint

Time frame:
baseline to Week 6
Reported as:
Count of participants · Participants
Cumulative Number of Subjects With Any of the Components of the Composite Endpoint: >2kg Increase in Body Weight (Office-based), >2 L Increase in Total Body Water, Increase in 2 or More Loop-diuretic Equivalents, Fluid Retention Adverse Event (AE)
ParticipantsZibo/DapaZiboPlacebo
Cumulative Number of Subjects With Any of the Components of the Composite Endpoint: >2kg Increase in Body Weight (Office-based), >2 L Increase in Total Body Water, Increase in 2 or More Loop-diuretic Equivalents, Fluid Retention Adverse Event (AE)14146
Statistical analysis
  • Zibo/Dapa vs Zibo · Proportions used for comparison · Risk difference (rd): 0 · 90% CI -0.24 to 0.24Risk difference for proportions presented. The associated CI is the exact unconditional 90% (two-sided) computed based on score statistic.
  • Zibo/Dapa vs Placebo · Proportions used for comparison · Risk difference (rd): 0.33 · 90% CI 0.09 to 0.55Risk difference for proportions presented. The associated CI is the exact unconditional 90% (two-sided) computed based on score statistic.
  • Zibo vs Placebo · Proportions used for comparison · Risk difference (rd): 0.33 · 90% CI 0.09 to 0.55Risk difference for proportions presented. The associated CI is the exact unconditional 90% (two-sided) computed based on score statistic.
SecondaryChange From Baseline in Body Weight

Change in site body weight

Time frame:
at Week 6
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight
kgZibo/DapaZiboPlacebo
Change From Baseline in Body Weight-1.08 (-1.88 to -0.28)0.64 (-0.11 to 1.39)-0.53 (-1.31 to 0.24)
Statistical analysis
  • Zibo/Dapa vs Zibo · Mixed Models Analysis · Mean difference (net): -1.72 · 90% CI -2.82 to -0.62Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo/Dapa vs Placebo · Mixed Models Analysis · Mean difference (net): -0.55 · 90% CI -1.66 to 0.56Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo vs Placebo · Mixed Models Analysis · Mean difference (net): 1.17 · 90% CI 0.09 to 2.25Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
SecondaryChange From Baseline in Body Fat Mass
Time frame:
at Week 6
Reported as:
Least squares mean · kg
Change From Baseline in Body Fat Mass
kgZibo/DapaZiboPlacebo
Change From Baseline in Body Fat Mass-1.68 (-2.43 to -0.94)-0.23 (-0.93 to 0.48)-0.30 (-1.03 to 0.42)
Statistical analysis
  • Zibo/Dapa vs Zibo · Mixed Models Analysis · Mean difference (net): -1.45 · 90% CI -2.48 to -0.43Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo/Dapa vs Placebo · Mixed Models Analysis · Mean difference (net): -1.38 · 90% CI -2.42 to -0.34Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo vs Placebo · Mixed Models Analysis · Mean difference (net): 0.07 · 90% CI -0.94 to 1.09Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
SecondaryChange From Baseline in Total Body Water
Time frame:
at Week 6
Reported as:
Least squares mean · L
Change From Baseline in Total Body Water
LZibo/DapaZiboPlacebo
Change From Baseline in Total Body Water0.36 (-0.22 to 0.94)0.66 (0.12 to 1.21)-0.36 (-0.92 to 0.21)
Statistical analysis
  • Zibo/Dapa vs Zibo · Mixed Models Analysis · Mean difference (net): -0.30 · 90% CI -1.10 to 0.49Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo/Dapa vs Placebo · Mixed Models Analysis · Mean difference (net): 0.72 · 90% CI -0.09 to 1.52Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo vs Placebo · Mixed Models Analysis · Mean difference (net): 1.02 · 90% CI 0.23 to 1.81Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
SecondaryChange From Baseline in Extracellular Water Volume
Time frame:
at Week 6
Reported as:
Least squares mean · L
Change From Baseline in Extracellular Water Volume
LZibo/DapaZiboPlacebo
Change From Baseline in Extracellular Water Volume0.38 (0.09 to 0.66)0.38 (0.11 to 0.65)-0.15 (-0.43 to 0.13)
Statistical analysis
  • Zibo/Dapa vs Zibo · Mixed Models Analysis · Mean difference (net): 0 · 90% CI -0.40 to 0.39Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo/Dapa vs Placebo · Mixed Models Analysis · Mean difference (net): 0.53 · 90% CI 0.12 to 0.93Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo vs Placebo · Mixed Models Analysis · Mean difference (net): 0.53 · 90% CI 0.14 to 0.92Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
SecondaryChange From Baseline in Intracellular Water Volume
Time frame:
at Week 6
Reported as:
Least squares mean · L
Change From Baseline in Intracellular Water Volume
LZibo/DapaZiboPlacebo
Change From Baseline in Intracellular Water Volume0.08 (-0.24 to 0.40)0.30 (0 to 0.60)-0.19 (-0.50 to 0.12)
Statistical analysis
  • Zibo/Dapa vs Zibo · Mixed Models Analysis · Mean difference (net): -0.22 · 90% CI -0.66 to 0.22Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo/Dapa vs Placebo · Mixed Models Analysis · Mean difference (net): 0.27 · 90% CI -0.18 to 0.71Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo vs Placebo · Mixed Models Analysis · Mean difference (net): 0.49 · 90% CI 0.05 to 0.92Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
SecondaryChange in Body Weight (kg) Over Time Course of Study

Change in home body weight

Time frame:
at Week 6
Reported as:
Least squares mean · kg
Change in Body Weight (kg) Over Time Course of Study
kgZibo/DapaZiboPlacebo
Change in Body Weight (kg) Over Time Course of Study-1.754 (-2.541 to -0.967)0.021 (-0.692 to 0.734)-1.256 (-2.077 to -0.435)
Statistical analysis
  • Zibo/Dapa vs Zibo · Mixed Models Analysis · Mean difference (net): -1.775 · 90% CI -2.836 to -0.714Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo/Dapa vs Placebo · Mixed Models Analysis · Mean difference (net): -0.499 · 90% CI -1.637 to 0.639Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo vs Placebo · Mixed Models Analysis · Mean difference (net): 1.277 · 90% CI 0.183 to 2.371Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
SecondaryChange in Total Dosage of Loop-diuretic Equivalents Use

One loop-diuretic equivalent = 40 mg furosemide = 1 mg bumetanide = 20 mg torsemide = 50 mg ethacrynic acid. In Japan, one loop-diuretic equivalent = 40 mg furosemide = 8 mg torsemide = 60 mg azosemide.

Time frame:
at Week 6
Reported as:
Least squares mean · Loop-diuretic *mg* equivalent
Change in Total Dosage of Loop-diuretic Equivalents Use
Loop-diuretic *mg* equivalentZibo/DapaZiboPlacebo
Change in Total Dosage of Loop-diuretic Equivalents Use1.282 (-2.045 to 4.609)6.340 (3.104 to 9.576)1.338 (-1.953 to 4.629)
Statistical analysis
  • Zibo/Dapa vs Zibo · Mixed Models Analysis · Mean difference (net): -5.058 · 90% CI -9.700 to -0.417Note: Model assumption was violated due to skewed data distribution and the results should not be interpreted.
  • Zibo/Dapa vs Placebo · Mixed Models Analysis · Mean difference (net): -0.056 · 90% CI -4.736 to 4.624Note: Model assumption was violated due to skewed data distribution and the results should not be interpreted.
  • Zibo vs Placebo · Mixed Models Analysis · Mean difference (net): 5.002 · 90% CI 0.388 to 9.617Note: Model assumption was violated due to skewed data distribution and the results should not be interpreted.
SecondaryCumulative Number of Subjects With Either of the Two Components of This Composite: 1. >3 L Increase in Total Body Water Volume From Baseline to Week 6 2. Increase in 3 or More Loop-diuretics Equivalents Use

Cumulative number of subjects with event of composite and the components of total body water and total dosage of loop-diuretic equivalents

Time frame:
from baseline to Week 6
Reported as:
Count of participants · Participants
Cumulative Number of Subjects With Either of the Two Components of This Composite: 1. >3 L Increase in Total Body Water Volume From Baseline to Week 6 2. Increase in 3 or More Loop-diuretics Equivalents Use
ParticipantsZibo/DapaZiboPlacebo
Cumulative Number of Subjects With Either of the Two Components of This Composite: 1. >3 L Increase in Total Body Water Volume From Baseline to Week 6 2. Increase in 3 or More Loop-diuretics Equivalents Use792
Statistical analysis
  • Zibo/Dapa vs Zibo · Proportions used for comparison · Risk difference (rd): -0.08 · 90% CI -0.31 to 0.15Risk difference for proportions presented. The associated CI is the exact unconditional 90% (two-sided) computed based on score statistic.
  • Zibo/Dapa vs Placebo · Proportions used for comparison · Risk difference (rd): 0.21 · 90% CI 0.02 to 0.41Risk difference for proportions presented. The associated CI is the exact unconditional 90% (two-sided) computed based on score statistic.
  • Zibo vs Placebo · Proportions used for comparison · Risk difference (rd): 0.29 · 90% CI 0.09 to 0.49Risk difference for proportions presented. The associated CI is the exact unconditional 90% (two-sided) computed based on score statistic.
SecondaryAbsolute Change in Systolic Blood Pressure
Time frame:
at Week 6
Reported as:
Least squares mean · mmHg
Absolute Change in Systolic Blood Pressure
mmHgZibo/DapaZiboPlacebo
Absolute Change in Systolic Blood Pressure-12.0 (-16.1 to -7.9)-2.6 (-6.5 to 1.2)-0.1 (-4.1 to 3.9)
Statistical analysis
  • Zibo/Dapa vs Zibo · Mixed Models Analysis · Mean difference (net): -9.4 · 90% CI -15.0 to -3.8Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo/Dapa vs Placebo · Mixed Models Analysis · Mean difference (net): -11.9 · 90% CI -17.7 to -6.1Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo vs Placebo · Mixed Models Analysis · Mean difference (net): -2.5 · 90% CI -8.1 to 3.0Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
SecondaryAbsolute Change in Diastolic Blood Pressure
Time frame:
at Week 6
Reported as:
Least squares mean · mmHg
Absolute Change in Diastolic Blood Pressure
mmHgZibo/DapaZiboPlacebo
Absolute Change in Diastolic Blood Pressure-9.1 (-11.3 to -6.8)-2.5 (-4.7 to -0.3)1.8 (-0.5 to 4.0)
Statistical analysis
  • Zibo/Dapa vs Zibo · Mixed Models Analysis · Mean difference (net): -6.5 · 90% CI -9.7 to -3.4Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo/Dapa vs Placebo · Mixed Models Analysis · Mean difference (net): -10.8 · 90% CI -14.1 to -7.6Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.
  • Zibo vs Placebo · Mixed Models Analysis · Mean difference (net): -4.3 · 90% CI -7.4 to -1.1Comparisons are done as Zibo adjusted Zibo/Dapa, Placebo adjusted Zibo/Dapa or Placebo adjusted Zibo.

Adverse events

Collected over Adverse events reported are adverse events with an onset date on or after the date of first dose of IP and until end of study for each participant which in general was 6 weeks treatment period and 2 weeks follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zibo/Dapa0/24 (0%)1/24 (4.2%)14/24 (58.3%)
Zibo0/24 (0%)2/24 (8.3%)15/24 (62.5%)
Placebo0/24 (0%)1/24 (4.2%)4/24 (16.7%)
Most frequent serious events
Most frequent serious events
EventZibo/DapaZiboPlacebo
Gastrointestinal haemorrhageGastrointestinal disorders0/242/240/24
AscitesGastrointestinal disorders0/240/241/24
Oesophageal varices haemorrhageGastrointestinal disorders1/240/240/24
Most frequent other events
Most frequent other events
EventZibo/DapaZiboPlacebo
HeadacheNervous system disorders5/246/241/24
Oedema peripheralGeneral disorders2/245/241/24
Fluid retentionMetabolism and nutrition disorders3/241/240/24
Orthostatic hypotensionVascular disorders3/242/240/24
Nasal congestionRespiratory, thoracic and mediastinal disorders2/243/240/24
AscitesGastrointestinal disorders1/243/240/24
Weight increasedInvestigations2/243/242/24
ThrombocytopeniaBlood and lymphatic system disorders2/240/240/24
ConstipationGastrointestinal disorders2/241/240/24
Dry mouthGastrointestinal disorders2/240/240/24

Baseline characteristics

Randomised subjects who received at least one dose of treatment.

Age, Continuous
Age, Continuous(Years)Zibo/DapaZiboPlaceboTotal
Mean60.2 ± 11.459.5 ± 8.962.6 ± 8.460.8 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Zibo/DapaZiboPlaceboTotal
Female68721
Male18161751
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zibo/DapaZiboPlaceboTotal
Hispanic or Latino4318
Not Hispanic or Latino20212364
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zibo/DapaZiboPlaceboTotal
American Indian or Alaska Native0000
Asian44412
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White20202060
More than one race0000
Unknown or Not Reported0000
08

Study locations

34 sites
  • Research Site
    Englewood, Colorado 80113, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    San Antonio, Texas 78215, United States
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Mitcham, 3132, Australia
  • Research Site
    Mechelen, 2800, Belgium
  • Research Site
    Liberec, 460 63, Czechia
  • Research Site
    Mladá Boleslav, 293 01, Czechia
  • Research Site
    Prague, 140 21, Czechia
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Milan, 20122, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Gifu, 500-8513, Japan
  • Research Site
    Kawasaki-shi, 215-0026, Japan
  • Research Site
    Kitakyusyu-shi, 806-8501, Japan
  • Research Site
    Nagaoka-shi, 940-2085, Japan
  • Research Site
    Niigata, 951-8520, Japan
  • Research Site
    Sapporo, 006-8555, Japan
  • Research Site
    Yokohama, 236-0004, Japan
  • Research Site
    Bydgoszcz, 85-794, Poland
  • Research Site
    Katowice, 40-081, Poland
  • Research Site
    Mysłowice, 41-400, Poland
  • Research Site
    Poznan, 61-848, Poland
  • Research Site
    Bratislava, 83104, Slovakia
  • Research Site
    Nitra, 950 01, Slovakia
  • Research Site
    Trnava, 91702, Slovakia
  • Research Site
    Aberdeen, AB25 2ZN, United Kingdom
  • Research Site
    Hull, HU3 2KZ, United Kingdom
  • Research Site
    Ipswich, IP4 5PD, United Kingdom
  • Research Site
    London, SE5 9RS, United Kingdom
  • Research Site
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Dec 2024, 9 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

Of 28 industry-sponsored phase 2 interventional studies under Liver Cirrhosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 27. This study's 9 months is below that.

Counting every sponsor, half of 55 studies reached it within 27 months; a quarter within 19 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 21, 2024
StartActual
Feb 15, 2024
Primary completionActual
Dec 11, 2024
CompletionActual
Dec 11, 2024
Results first posted
Jan 20, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06269484
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 21, 2024
Start date
Feb 15, 2024
Primary completion
Dec 11, 2024
Completion
Dec 11, 2024
Results posted
Jan 20, 2026
Last update
Jan 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ZD4054 · Dapagliflozin

Start the discussion